ES2168295T3 - Factor estimulante oseo. - Google Patents
Factor estimulante oseo.Info
- Publication number
- ES2168295T3 ES2168295T3 ES94908917T ES94908917T ES2168295T3 ES 2168295 T3 ES2168295 T3 ES 2168295T3 ES 94908917 T ES94908917 T ES 94908917T ES 94908917 T ES94908917 T ES 94908917T ES 2168295 T3 ES2168295 T3 ES 2168295T3
- Authority
- ES
- Spain
- Prior art keywords
- gly
- polypeptide
- ala
- glu
- minor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
UNA SUSTANCIA DE POLIPEPTIDO AISLADA DE SUERO DE RATA QUE, AL ADMINISTRAR A RATAS INCAPACES DE PRODUCIR PTH (RATAS PARATIROIDEMIZADAS), PRODUCE UN AUMENTO EN LA PROPORCION DE AÑADIDO MINERAL DE HUESO. LAS SUSTANCIA HA SIDO AISLADA EN DOS FORMAS, UNA PRIMER POLIPEPTIDO MAYOR QUE TIENE UN PESO MOLECULAR DE APROXIMADAMENTE EL DOBLE DEL DE UN SEGUNDO POLIPEPTIODO MENOR. LOS 11 PRIMEROS AMINOACIDOS DE LA SECUENCIA DEL POLIPEPTIDO MENOR HAN SIDO DETERMINADOS SON GLY PRO GLY GLY ALA GLY GLU TH LYS PRO ILE. LOS 7 PRIMEROS AMINOACIDOS DEL POLIPEPTIDO MAYOR HAN SIDO DETERMINADOS Y SON GLY PRO GLY CLY ALA GLY GLU. EL POLIPEPTIDO MAYOR PUEDE SER EL DIMERO DEL POLPEPTIDO MENOR. UNA ONDA DE ACIDO NUCLEICO, BASADA EN LA SECUENCIA DE AMINOACIDOS DEL PEPTIDO DE RATA FUE USADA PARA FILTRAR UNA LIBRERIA FETAL DE ADNC DE HIGADO HUMANO. UN POLIPEPTIDO FUE ASI QUIMICAMENTE SINTETIZADO DE ACUERDO CON LA SECUENCIA GLY ILE GLY GLY ARG THR ASN GLU HIS THR ALA ASP CYS LYS ILE LYS PRO ASN THR LEU HIS LYS ALA ALA GLU THR LEU MET VAL LEU ASP GLN ASN GLN PRO. LA PROPORCION DE AÑADIDO DE HUESO EN LAS RATAS AUMENTA EN UNA DOSIS QUE DEPENDE DEL MODO DE ADMINISTRACION DE ESTE COMPUESTO QUIMICAMENTE SINTETIZADO.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3138693A | 1993-03-12 | 1993-03-12 | |
| US12021793A | 1993-09-13 | 1993-09-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2168295T3 true ES2168295T3 (es) | 2002-06-16 |
Family
ID=26707172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES94908917T Expired - Lifetime ES2168295T3 (es) | 1993-03-12 | 1994-03-14 | Factor estimulante oseo. |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0688360B1 (es) |
| JP (1) | JP3733381B2 (es) |
| KR (1) | KR960701201A (es) |
| CN (1) | CN1119457A (es) |
| AT (1) | ATE208818T1 (es) |
| AU (1) | AU678441B2 (es) |
| BR (1) | BR9406447A (es) |
| CA (1) | CA2157901A1 (es) |
| CZ (1) | CZ234295A3 (es) |
| DE (1) | DE69429082T2 (es) |
| ES (1) | ES2168295T3 (es) |
| FI (1) | FI954252A0 (es) |
| HU (1) | HUT73297A (es) |
| IL (1) | IL108947A0 (es) |
| NO (1) | NO953286L (es) |
| NZ (1) | NZ262352A (es) |
| PL (1) | PL182236B1 (es) |
| TW (1) | TW385314B (es) |
| WO (1) | WO1994020615A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5786327A (en) | 1993-03-12 | 1998-07-28 | Gensci Regeneration Sciences Inc. | Bone stimulating factor, methods of isolating same, and methods of increasing bone growth comprising administering same |
| US6117839A (en) * | 1995-06-07 | 2000-09-12 | Gensci Regeneration Sciences, Inc. | Bone stimulating factor |
| US5880094A (en) * | 1995-06-07 | 1999-03-09 | Osteopharm Limited | Polypeptides that stimulate bone growth |
| US6352973B1 (en) | 1995-06-07 | 2002-03-05 | Osteopharm Inc. | Bone stimulating factor |
| US6693081B2 (en) * | 1995-09-26 | 2004-02-17 | Osteopharm Inc. | Bone stimulating factor |
| ATE417927T1 (de) | 1997-07-30 | 2009-01-15 | Univ Emory | Neue knochenmineralisierungsproteine, dna, vektoren, expressionssysteme |
| EP1015565B1 (en) | 1997-09-19 | 2006-04-12 | Metabolix, Inc. | Biological systems for manufacture of polyhydroxyalkanoate polymers containing 4-hydroxyacids |
| DE19906096A1 (de) | 1999-02-13 | 2000-08-17 | Walter Sebald | Protein mit einem Heparin-bindenden Epitop |
| AU5379200A (en) * | 1999-06-02 | 2000-12-28 | Osteopharm Inc. | Bone stimulating factor |
| EP1212464B1 (en) | 1999-08-30 | 2006-02-22 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for osteoporosis |
| US6815421B1 (en) | 2001-03-22 | 2004-11-09 | Osteopharm Inc. | Polypeptides for use in ameliorating effects of aging in mammals |
| DE602004030367D1 (de) | 2003-08-08 | 2011-01-13 | Interleukin Genetics Inc | Diagnostikum für osteoporose |
| DK2118136T3 (da) * | 2006-12-21 | 2010-11-15 | Corticalis As | Konsensuspeptid |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1229789A (en) * | 1983-06-06 | 1987-12-01 | David Baylink | Polypeptides exhibiting skeletal growth factor activity |
| CA2020729A1 (en) * | 1989-07-19 | 1991-01-20 | Michael C. Kiefer | Bone morphogenetic protein |
-
1994
- 1994-03-11 IL IL10894794A patent/IL108947A0/xx unknown
- 1994-03-14 NZ NZ262352A patent/NZ262352A/en unknown
- 1994-03-14 HU HU9502659A patent/HUT73297A/hu unknown
- 1994-03-14 DE DE69429082T patent/DE69429082T2/de not_active Expired - Fee Related
- 1994-03-14 KR KR1019950703855A patent/KR960701201A/ko not_active Ceased
- 1994-03-14 JP JP51844794A patent/JP3733381B2/ja not_active Expired - Fee Related
- 1994-03-14 WO PCT/CA1994/000144 patent/WO1994020615A1/en not_active Ceased
- 1994-03-14 CN CN94191456A patent/CN1119457A/zh active Pending
- 1994-03-14 CA CA002157901A patent/CA2157901A1/en not_active Abandoned
- 1994-03-14 BR BR9406447A patent/BR9406447A/pt not_active Application Discontinuation
- 1994-03-14 AU AU61797/94A patent/AU678441B2/en not_active Ceased
- 1994-03-14 PL PL94310617A patent/PL182236B1/pl unknown
- 1994-03-14 EP EP94908917A patent/EP0688360B1/en not_active Expired - Lifetime
- 1994-03-14 AT AT94908917T patent/ATE208818T1/de not_active IP Right Cessation
- 1994-03-14 CZ CZ952342A patent/CZ234295A3/cs unknown
- 1994-03-14 ES ES94908917T patent/ES2168295T3/es not_active Expired - Lifetime
- 1994-03-21 TW TW083102552A patent/TW385314B/zh not_active IP Right Cessation
-
1995
- 1995-08-22 NO NO953286A patent/NO953286L/no not_active Application Discontinuation
- 1995-09-11 FI FI954252A patent/FI954252A0/fi unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE208818T1 (de) | 2001-11-15 |
| JP3733381B2 (ja) | 2006-01-11 |
| DE69429082D1 (de) | 2001-12-20 |
| EP0688360A1 (en) | 1995-12-27 |
| NO953286D0 (no) | 1995-08-22 |
| CZ234295A3 (en) | 1996-04-17 |
| AU678441B2 (en) | 1997-05-29 |
| JPH08508158A (ja) | 1996-09-03 |
| HUT73297A (en) | 1996-07-29 |
| CN1119457A (zh) | 1996-03-27 |
| BR9406447A (pt) | 1996-02-13 |
| NO953286L (no) | 1995-10-25 |
| EP0688360B1 (en) | 2001-11-14 |
| DE69429082T2 (de) | 2002-07-25 |
| CA2157901A1 (en) | 1994-09-15 |
| PL310617A1 (en) | 1995-12-27 |
| WO1994020615A1 (en) | 1994-09-15 |
| KR960701201A (ko) | 1996-02-24 |
| IL108947A0 (en) | 1994-06-24 |
| FI954252A7 (fi) | 1995-09-11 |
| PL182236B1 (pl) | 2001-11-30 |
| FI954252A0 (fi) | 1995-09-11 |
| AU6179794A (en) | 1994-09-26 |
| NZ262352A (en) | 1997-10-24 |
| TW385314B (en) | 2000-03-21 |
| HU9502659D0 (en) | 1995-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2168295T3 (es) | Factor estimulante oseo. | |
| ES2202899T3 (es) | Agregados de derivados de la insulina humana. | |
| Hiltz et al. | α-MSH peptides inhibit acute inflammation induced in mice by rIL-1β, rIL-6, rTNF-α and endogenous pyrogen but not that caused by LTB4, PAF and rIL-8 | |
| US5223481A (en) | Biologically active lipoprotein and its use | |
| CA2215739A1 (en) | Lipophilic peptide hormone derivatives | |
| KR850007559A (ko) | 조절 펩타이드의 삽입식 제형 | |
| Carsten et al. | Actin: a comparative study | |
| ES2070322T3 (es) | Polipeptidos biologicamente activos basados en las secuencias del factor de crecimiento de transformacion beta. | |
| AU5963290A (en) | Inhibition of the n-end rule pathway in living cells | |
| BR9807618A (pt) | Análogo de fator xdelta, dna recombinante codificante para um análogo de fator xdelta, células transformadas, preparação, uso da mesma, e, processos para produzir uma preparação contendo análogo de fator xdelta recombinante purificado e análogo de fator xa. | |
| Houck et al. | THE EFFECT OF SODIUM DILANTIN ADMINISTRATION UPON THE CHEMISTY OF THE SKIN | |
| EP0357067A3 (en) | Recombinant natural killer cell activator | |
| ATE10364T1 (de) | Retro-inverso analoga von c-terminalen pentaund hexapeptiden der verbindung p. | |
| KR950702573A (ko) | 공유결합된 항산화제를 갖는 합성 펩티드 폐 계면활성제(Synthetic Peptide Lung Surfactants Having Covalently Bonded Antioxidants) | |
| AR057639A2 (es) | Analogos del peptido 1- similar al glucagon uso de los mismos par ala manufactura de un medicamento y composiciones farmaceuticas que los contienen | |
| ATE226250T1 (de) | Polypeptide und peptide dafür kodierende nukleinsaüre und ihre verwendung im zusammenhang mit tumortherapie, entzündung oder immunology | |
| DE69837159D1 (de) | Verfahren zur herstellung einer einzeldosisspritze mit lyophilisierter proteinmischung zur verabreichung eines volumens von weniger als 0,5 ml | |
| KR950702574A (ko) | 펩티드 폐 계면활성제 및 치료용 혼합물(Peptide Lung Surfactants and Therapeutic Combinations) | |
| OTSUKA et al. | Synthesis of an octadecapeptide and its 18-amide analog corresponding to the first eighteen amino acid residues of corticotropin (ACTH), and their biological activities | |
| GB1374379A (en) | Process for producing polypeptides | |
| BR0014803A (pt) | Peptìdeo, composição farmacêutica, uso de um ou mais dos peptìdeos, e, composição de diagnóstico | |
| Barker et al. | Metabolic effects of some halogenated acrylic acid analogues of thyroxine | |
| KR960706503A (ko) | CXC 인터크린 분자의 펩타이드 억제제(Peptide inhibitors of CXC intercrine molecules) | |
| Schlueter et al. | Thyrocalcitonin: bioassay characteristics of purified preparations | |
| Sobolewski et al. | Heterogeneity of collagen isolated from methylcholanthrene-induced sarcoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 688360 Country of ref document: ES |